// App-Quantinova.ai

: BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).

Researchers

Presenter

  • Scott Kopetz

Principal Investigators

  • Tae Won Kim

  • Rona Yaeger

  • Jayesh Desai

  • Harpreet Singh Wasan

  • Eric Van Cutsem

  • Fortunato Ciardiello

  • Tim Maughan

  • Cathy Eng

  • Jeanne Tie

  • Elena Elez

  • Sara Lonardi

  • Xiaosong Zhang

  • Chin-Hee Chung

  • Tiziana Usari

  • Tim Nicholz

  • Danielle A. Murphy

  • Josep Tabernero

Medical Centers

  • Oxford University, Oxford, United Kingdom

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • NSABP/NRG Oncology and Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Pfizer Inc, San Diego, CA

  • Pfizer Inc, New York, NY

  • Pfizer Inc, San Diego, CA

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • Peter McCallum Hospital, Melbourne, Australia

  • Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

  • Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Pfizer Inc, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Universita Della Campania "Luigi Vanvitelli", Napoli, Italy

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, Japan

  • Pfizer Inc, Milan, Italy

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

Locations

  • United Kingdom

  • Australia

  • Republic of South Korea

  • United States

  • Belgium

  • Italy

  • Japan

  • Spain

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Microsatellite instability

  • Circulating DNA

Drug/Treatment

  • Encorafenib

  • Oxaliplatin

  • Irinotecan

  • Erbitux

  • mFOLFOX6

  • FOLFIRI

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • III

Study Id's

  • NCT02928224

  • NCT03693170

  • NCT04607421

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved